Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review)

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 933-943

  Papageorgis, Panagiotis ^a,b   Stylianopoulos, Triantafyllos ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b EUROPEAN UNIVERSITY CYPRUS   (Cyprus)

Author keywords

Cancer therapy; Cancer associated fibroblasts; Desmoplasia; Extracellular matrix; Immune cells

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG REPOSITIONING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG REPOSITIONING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84921916417     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2816     Document Type: Article

References (184)

1. Derynck R and Akhurst RJ: Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 9: 1000-1004, 2007.
2. Wakefield LM and Hill CS: Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat Rev Cancer 13: 328-341, 2013.
3. Massagué J, Seoane J and Wotton D: Smad transcription factors. Genes Dev 19: 2783-2810, 2005.
4. Annes JP, Munger JS and Rifkin DB: Making sense of latent TGFbeta activation. J Cell Sci 116: 217-224, 2003.
5. Gleizes PE, Beavis RC, Mazzieri R, Shen B and Rifkin DB: Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem 271: 29891-29896, 1996.
6. Miyazono K, Olofsson A, Colosetti P and Heldin CH: A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 10: 1091-1101, 1991.
7. Saharinen J, Taipale J and Keski-Oja J: Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J 15: 245-253, 1996.
8. Unsöld C, Hyytiäinen M, Bruckner-Tuderman L and Keski-Oja J: Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 114: 187-197, 2001.
9. Nunes I, Gleizes PE, Metz CN and Rifkin DB: Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 136: 1151-1163, 1997.
10. Lawrence DA, Pircher R, Krycève-Martinerie C and Jullien P: Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 121: 184-188, 1984.
11. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93: 1159-1170, 1998.
12. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M and Murphy-Ullrich JE: The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274: 13586-13593, 1999.
13. Dubois CM, Laprise MH, Blanchette F, Gentry LE and Leduc R: Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270: 10618-10624, 1995.
14. Sato Y and Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 109: 309-315, 1989.
15. Yu Q and Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000.
16. Derynck R, Zhang Y and Feng XH: Smads: transcriptional activators of TGF-beta responses. Cell 95: 737-740, 1998.
17. Massagué J: TGF-beta signal transduction. Annu Rev Biochem 67: 753-791, 1998.
18. Riggins GJ, Thiagalingam S, Rozenblum E, et al: Mad-related genes in the human. Nat Genet 13: 347-349, 1996.
19. Lagna G, Hata A, Hemmati-Brivanlou A and Massagué J: Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383: 832-836, 1996.
20. Nakao A, Imamura T, Souchelnytskyi S, et al: TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 16: 5353-5362, 1997.
21. Heldin CH, Miyazono K and ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
22. Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520, 2006.
23. Lewis KA, Gray PC, Blount AL, et al: Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404: 411-414, 2000.
24. Wrana JL, Attisano L, Wieser R, Ventura F and Massagué J: Mechanism of activation of the TGF-beta receptor. Nature 370: 341-347, 1994.
25. Shi Y and Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700, 2003.
26. Miyazono K, Maeda S and Imamura T: BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16: 251-263, 2005.
27. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584, 2003.
28. Abdollah S, Macías-Silva M, Tsukazaki T, Hayashi H, Attisano L and Wrana JL: TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272: 27678-27685, 1997.
29. Zhang Y, Feng X, We R and Derynck R: Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 383: 168-172, 1996.
30. Tsukazaki T, Chiang TA, Davison AF, Attisano L and Wrana JL: SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95: 779-791, 1998.
31. Feng XH, Zhang Y, Wu RY and Derynck R: The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 12: 2153-2163, 1998.
32. Janknecht R, Wells NJ and Hunter T: TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 12: 2114-2119, 1998.
33. Itoh S, Ericsson J, Nishikawa J, Heldin CH and ten Dijke P: The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. Nucleic Acids Res 28: 4291-4298, 2000.
34. Bai RY, Koester C, Ouyang T, et al: SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. Nat Cell Biol 4: 181-190, 2002.
35. Chen CR, Kang Y, Siegel PM and Massagué J: E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110: 19-32, 2002.
36. Kang Y, Chen CR and Massagué J: A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 11: 915-926, 2003.
37. Wotton D, Knoepfler PS, Laherty CD, Eisenman RN and Massagué J: The Smad transcriptional corepressor TGIF recruits mSin3. Cell Growth Differ 12: 457-463, 2001.
38. Akiyoshi S, Inoue H, Hanai J, et al: c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem 274: 35269-35277, 1999.
39. Luo K, Stroschein SL, Wang W, et al: The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev 13: 2196-2206, 1999.
40. Stroschein SL, Wang W, Zhou S, Zhou Q and Luo K: Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286: 771-774, 1999.
41. Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF and Weinberg RA: Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Mol Cell 4: 499-509, 1999.
42. Seoane J, Le HV, Shen L, Anderson SA and Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223, 2004.
43. Pardali K, Kurisaki A, Morén A, ten Dijke P, Kardassis D and Moustakas A: Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275: 29244-29256, 2000.
44. Zhang Y, Feng XH and Derynck R: Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 394: 909-913, 1998.
45. Lin X, Liang YY, Sun B, et al: Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription. Mol Cell Biol 23: 9081-9093, 2003.
46. Peng Y, Zhao S, Song L, Wang M and Jiao K: Sertad1 encodes a novel transcriptional co-activator of SMAD1 in mouse embryonic hearts. Biochem Biophys Res Commun 441: 751-756, 2013.
47. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K and Hirai H: The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 97: 2815-2822, 2001.
48. Xi Q, Wang Z, Zaromytidou AI, et al: A poised chromatin platform for TGF-β access to master regulators. Cell 147: 1511-1524, 2011.
49. Ross S, Cheung E, Petrakis TG, Howell M, Kraus WL and Hill CS: Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. EMBO J 25: 4490-4502, 2006.
50. Papageorgis P, Lambert AW, Ozturk S, et al: Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 70: 968-978, 2010.
51. Nakao A, Afrakhte M, Morén A, et al: Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389: 631-635, 1997.
52. Itóh S, Landström M, Hermansson A, et al: Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 273: 29195-29201, 1998.
53. Hayashi H, Abdollah S, Qiu Y, et al: The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89: 1165-1173, 1997.
54. Ebisawa T, Fukuchi M, Murakami G, et al: Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276: 12477-12480, 2001.
55. Kavsak P, Rasmussen RK, Causing CG, et al: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6: 1365-1375, 2000.
56. Zhang S, Fei T, Zhang L, et al: Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 27: 4488-4499, 2007.
57. Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res 19: 128-139, 2009.
58. Hartsough MT and Mulder KM: Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem 270: 7117-7124, 1995.
59. Frey RS and Mulder KM: TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells. Cancer Lett 117: 41-50, 1997.
60. Papageorgis P, Cheng K, Ozturk S, et al: Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 71: 998-1008, 2011.
61. Finlay GA, Thannickal VJ, Fanburg BL and Paulson KE: Transforming growth factor-beta 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor. J Biol Chem 275: 27650-27656, 2000.
62. Vinals F andPouysségur J: Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol 21: 7218-7230, 2001.
63. Ellenrieder V, Hendler SF, Boeck W, et al: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228, 2001.
64. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME and Moses HL: Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6: 603-610, 2004.
65. Lee MK, Pardoux C, Hall MC, et al: TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMJO J 26: 3957-3967, 2007.
66. Liao JH, Chen JS, Chai MQ, Zhao S and Song JG: The involvement of p38 MAPK in transforming growth factor beta1-induced apoptosis in murine hepatocytes. Cell Res 11: 89-94, 2001.
67. Kimura N, Matsuo R, Shibuya H, Nakashima K and Taga T: BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275: 17647-17652, 2000.
68. Bakin AV, Rinehart C, Tomlinson AK and Arteaga CL: p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115: 3193-3206, 2002.
69. Hocevar BA, Brown TL and Howe PH: TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMJO J 18: 1345-1356, 1999.
70. Yu L, Hébert MC and Zhang YE: TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMJO J 21: 3749-3759, 2002.
71. Yamaguchi K, Shirakabe K, Shibuya H, et al: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270: 2008-2011, 1995.
72. Shim JH, Xiao C, Paschal AE, et al: TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19: 2668-2681, 2005.
73. Sorrentino A, Thakur N, Grimsby S, et al: The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 10: 1199-1207, 2008.
74. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z and Zhang YE: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 31: 918-924, 2008.
75. Zhang L, Wang W, Hayashi Y, et al: A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMJO J 22: 4443-4454, 2003.
76. Kim KY, Kim BC, Xu Z and Kim SJ: Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells. J Biol Chem 279: 29478-29484, 2004.
77. Jaffe AB and Hall A: Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21: 247-269, 2005.
78. Bhowmick NA, Ghiassi M, Bakin A, et al: Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27-36, 2001.
79. Edlund S, Landström M, Heldin CH and Aspenström P: Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13: 902-914, 2002.
80. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y and Wrana JL: Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science307: 1603-1609, 2005.
81. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL and Arteaga CL: Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275: 36803-36810, 2000.
82. Shin I, Bakin AV, Rodeck U, Brunet A and Arteaga CL: Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12: 3328-3339, 2001.
83. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000.
84. Lamouille S and Derynck R: Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178: 437-451, 2007.
85. Roberts AB and Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623, 2003.
86. Tang B, Vu M, Booker T, et al: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-1124, 2003.
87. Wakefield LM and Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29, 2002.
88. Siegel PM, Shu W, Cardiff RD, Muller WJ and Massagué J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435, 2003.
89. Siegel PM and Massagué J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821, 2003.
90. Choi ME and Ballermann BJ: Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J Biol Chem 270: 21144-21150, 1995.
91. Hyman KM, Seghezzi G, Pintucci G, et al: Transforming growth factor-beta1 induces apoptosis in vascular endothelial cells by activation of mitogen-activated protein kinase. Surgery 132: 173-179, 2002.
92. Rich JN, Zhang M, Datto MB, Bigner DD and Wang XF: Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 274: 35053-35058, 1999.
93. Yang X, Letterio JJ, Lechleider RJ, et al: Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMJO J 18: 1280-1291, 1999.
94. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM and Massagué J: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185, 1990.
95. Hannon GJ and Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257-261, 1994.
96. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y and Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92: 5545-5549, 1995.
97. Polyak K, Kato JY, Solomon MJ, et al: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
98. Pietenpol JA, Stein RW, Moran E, et al: TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61: 777-785, 1990.
99. Norton JD: ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113: 3897-3905, 2000.
100. Grotendorst GR: Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 8: 171-179, 1997.
101. Park K, Kim SJ, Bang YJ, et al: Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci USA 91: 8772-8776, 1994.
102. Kim IY, Ahn HJ, Zelner DJ, et al: Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 56: 44-48, 1996.
103. Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
104. Riggins GJ, Kinzler KW, Vogelstein B and Thiagalingam S: Frequency of Smad gene mutations in human cancers. Cancer Res 57: 2578-2580, 1997.
105. Schutte M, Hruban RH, Hedrick L, et al: DPC4 gene in various tumor types. Cancer Res 56: 2527-2530, 1996.
106. Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543-552, 1996.
107. Hahn SA, Hoque AT, Moskaluk CA, et al: Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56: 490-494, 1996.
108. Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996.
109. Thiagalingam S, Lengauer C, Leach FS, et al: Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13: 343-346, 1996.
110. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al: Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 97: 9624-9629, 2000.
111. Kretzschmar M, Doody J, Timokhina I and Massagué J: A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 13: 804-816, 1999.
112. Kretzschmar M, Doody J and Massagué J: Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389: 618-622, 1997.
113. Massagué J: Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev 17: 2993-2997, 2003.
114. Gomis RR, Alarcón C, Nadal C, Van Poznak C and Massagué J: C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10: 203-214, 2006.
115. Padua D, Zhang XH, Wang Q, et al: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77, 2008.
116. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
117. Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.
118. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
119. Cano A, Pérez-Moreno MA, Rodrigo I, et al: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
120. Savagner P, Yamada KM and Thiery JP: The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 137: 1403-1419, 1997.
121. Eger A, Aigner K, Sonderegger S, et al: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24: 2375-2385, 2005.
122. Comijn J, Berx G, Vermassen P, et al: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7: 1267-1278, 2001.
123. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH and Moustakas A: Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174: 175-183, 2006.
124. Mani SA, Yang J, Brooks M, et al: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104: 10069-10074, 2007.
125. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.
126. Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.
127. Zhu B, Fukada K, Zhu H and Kyprianou N: Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res 66: 8640-8647, 2006.
128. Deckers M, van Dinther M, Buijs J, et al: The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202-2209, 2006.
129. Kang Y and Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279, 2004.
130. Grande JP: Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 214: 27-40, 1997.
131. Singer AJ and Clark RA: Cutaneous wound healing. N Engl J Med 341: 738-746, 1999.
132. Pickup M, Novitskiy S and Moses HL: The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13: 788-799, 2013.
133. Dalal BI, Keown PA and Greenberg AH: Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381-389, 1993.
134. Kingsley LA, Fournier PG, Chirgwin JM and Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther 6: 2609-2617, 2007.
135. Prud'homme GJ: Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87: 1077-1091, 2007.
136. Wrzesinski SH, Wan YY and Flavell RA: Transforming growth factor-beta and the immune response: implications for anti-cancer therapy. Clin Cancer Res 13: 5262-5270, 2007.
137. Akhurst RJ and Hata A: Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 11: 790-811, 2012.
138. Flavell RA, Sanjabi S, Wrzesinski SH and Licona-Limón P: The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10: 554-567, 2010.
139. Laouar Y, Sutterwala FS, Gorelik L and Flavell RA: Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 6: 600-607, 2005.
140. Rubtsov YP and Rudensky AY: TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7: 443-453, 2007.
141. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
142. Gong D, Shi W, Yi SJ, Chen H, Groffen J and Heisterkamp N: TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol 13: 31, 2012.
143. Fridlender ZG, Sun J, Kim S, et al: Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194, 2009.
144. Yamaguchi Y, Tsumura H, Miwa M and Inaba K: Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15: 144-153, 1997.
145. Ramesh S, Wildey GM and Howe PH: Transforming growth factor beta (TGFbeta)-induced apoptosis: the rise & fall of Bim. Cell Cycle 8: 11-17, 2009.
146. Marcoe JP, Lim JR, Schaubert KL, et al: TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol 13: 843-850, 2012.
147. Wipff PJ, Rifkin DB, Meister JJ and Hinz B: Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 179: 1311-1323, 2007.
148. Wipff PJ and Hinz B: Myofibroblasts work best under stress. J Bodyw Mov Ther 13: 121-127, 2009.
149. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C and Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363, 2002.
150. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH and Diamandis EP: Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 10: 1403-1418, 2012.
151. Paszek MJ, Zahir N, Johnson KR, et al: Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254, 2005.
152. Samuel MS, Lopez JI, McGhee EJ, et al: Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 19: 776-791, 2011.
153. Branton MH and Kopp JB: TGF-beta and fibrosis. Microbes Infect 1: 1349-1365, 1999.
154. Egeblad M, Rasch MG and Weaver VM: Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 22: 697-706, 2010.
155. Smith NR, Baker D, Farren M, et al: Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res 19: 6943-6956, 2013.
156. Stylianopoulos T and Jain RK: Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA 110: 18632-18637, 2013.
157. Stylianopoulos T, Martin JD, Chauhan VP,et al : Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 109: 15101-15108, 2012.
158. Demou ZN: Gene expression profiles in 3D tumor analogs indicate compressive strain differentially enhances metastatic potential. Ann Biomed Eng 38: 3509-3520, 2010.
159. Tse JM, Cheng G, Tyrrell JA, et al: Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci USA 109: 911-916, 2012.
160. Chauhan VP, Martin JD, Liu H, et al: Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. Nat Commun 4: 2516, 2013.
161. Facciabene A, Peng X, Hagemann IS, et al: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475: 226-230, 2011.
162. Wilson WR and Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410, 2011.
163. Jain RK, Martin JD and Stylianopoulos T: The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 16: 321-346, 2014.
164. Jain RK and Stylianopoulos T: Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7: 653-664, 2010.
165. Chauhan VP and Jain RK: Strategies for advancing cancer nanomedicine. Nat Mater 12: 958-962, 2013.
166. Popović Z, Liu W, Chauhan VP, et al: A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl 49: 8649-8652, 2010.
167. Stylianopoulos T, Poh MZ, Insin N, et al: Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J 99: 1342-1349, 2010.
168. Zhong Z, Carroll KD, Policarpio D, et al: Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16: 1191-1205, 2010.
169. Uhl M, Aulwurm S, Wischhusen J, et al: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961, 2004.
170. Kim S, Buchlis G, Fridlender ZG, et al: Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 68: 10247-10256, 2008.
171. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S and Prud'homme GJ: Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs 20: 334-345, 2009.
172. Achyut BR, Bader DA, Robles AI, et al: Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet 9: e1003251, 2013.
173. Bragado P, Estrada Y, Parikh F, et al: TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat Cell Biol 15: 1351-1361, 2013.
174. Biswas T, Gu X, Yang J, Ellies LG and Sun LZ: Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346: 129-138, 2014.
175. Stockmann C, Doedens A, Weidemann A, et al: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456: 814-818, 2008.
176. Rhim AD, Mirek ET, Aiello NM, et al: EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361, 2012.
177. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y and Jain RK: Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 108: 2909-2914, 2011.
178. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R and Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135: 1429-1435, 2009.
179. Keizman D, Huang P, Eisenberger MA, et al: Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 47: 1955-1961, 2011.
180. Nakai Y, Isayama H, Ijichi H, et al: Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci 103: 1489-1492, 2012.
181. Liu J, Liao S, Diop-Frimpong B, et al: TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA 109: 16618-16623, 2012.
182. Kozono S, Ohuchida K, Eguchi D, et al: Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res 73: 2345-2356, 2013.
183. Bouquet F, Pal A, Pilones KA, et al: TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17: 6754-6765, 2011.
184. Zhang M, Kleber S, Röhrich M, et al: Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71: 7155-7167, 2011.